SRSF1 and neoplasm: Given the dual role of SRSF1 on tumor and T cells, we selected the significant candidate inhibitors screening by cytotoxicity assays in vitro and added into CD8+T cells at single dose (100 μM), we found that only TN2008, T4613 and T2987 have more effects on upregulation of CD8 + T cell (Fig. 5c, d).